Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer

Kim, RD; Alberts, SR; Pena, C; Genvresse, I; Ajavon-Hartmann, A; Xia, C; Kelly, A; Grilley-Olson, JE

Kim, RD (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, 12902 USF Magnolia Dr,1, Tampa, FL 33612 USA.

BRITISH JOURNAL OF CANCER, 2018; 118 (4): 462

Abstract

Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-alpha/delta activity that has demonstrate......

Full Text Link